- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Heart Failure
The Practical Cardiology(TM) Heart Failure clinical resource center is an information hub for the latest in heart failure and heart failure management. With a focus on heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF) this page features content including articles, videos, podcasts, and clinician-authored columns on FDA approvals, studies, guideline updates, and more.
Cardiology Month in Review: September 2021
September 25, 2021
September's cardiology month in review features FDA news relted to empagliflozin and tofacitinib, a study into the potential impact of sacubitril/valsartan's label expansion, and a study from HFSA 2021.
Sacubitril/Valsartan Label Expansion Could Increase Patient Base by Nearly 2 Million
September 21, 2021
An analysis leveraging data from NHANES, the GWTG-HF registry, and PARAGON-HF is providing insight into the potential impact of the FDA's expanded label for sacubitril/valsartan based on optimal implementation.
Digital Apps Could Improve Outcomes, Adherence Among Patients With Heart Failure
September 17, 2021
Data from the CONNECT-HF trial from HFSA 2021 suggest use of a digital tool designed to improve adherence could contribute to improving outcomes among patients discharged from the hospital with heart failure with reduced ejection fraction.
Matthew Budoff, MD: Need for Greater Uptake of Newer Medications
September 15, 2021
Matthew Budoff, MD, discusses what he views as hurdles to achieving optimal prescription of newer agents in the treatment of cardiometabolic conditions, including diabetes, heart failure, dyslipidemia, and more.
PRESERVED-HF: Dapagliflozin Reduces Symptom Burden, Physical Limitations in HFpEF
September 14, 2021
Presented at HFSA 2021, PRESERVED-HF provides evidence suggesting dapagliflozin use was associated with improvements in KCCQ symptom score and 6-minute walking distance in patients with heart failure with preserved ejection fraction.
FDA Grants Empagliflozin Breakthrough Therapy Designation for HFpEF
September 09, 2021
Announced by Boehringer Ingelheim and Eli Lilly and Company on September 9, the Breakthrough Therapy designation for empagliflozin is based on the results of the EMPEROR-Preserved trial.
ESC Congress 2021 Expert Perspective: Top 5 Studies With Brett Nowlan, MD
September 02, 2021
Practical Cardiology editorial advisory board member Brett Nowlan, MD, compiled a top 5 list of studies he thought were noteworthy from ESC Congress 2021 and offers his perspective on why he chose each study.
ESC Congress 2021: Top Trials Slideshow
August 31, 2021
Every year, ESC Congress provides clinicians and researchers with a glimpse into the latest data from clinical trials. Our editorial staff's top picks for new trials from ESC Congress 2021 conference includes EMPEROR-Preserved, FIGARO-DKD, SSaSS, MASTER DAPT, and the LOOP Study.
Q&A on EMPEROR-Preserved With Javed Butler, MD
August 27, 2021
In an interview with Practical Cardiology, Javed Butler, MD, offers his perspective on the results of EMPEROR-Preserved and reflects on their rapid ascent into the cardiometabolic spotlight, evidenced by headlining trials at ESC Congress for the past 3 years.
EMPEROR-Preserved: Empagliflozin Proves Benefit in HFpEF
August 27, 2021
Results of EMPEROR-Preserved demonstrate use of empagliflozin was associated with a 21% reduction in the composite end point of hospitalization for heart failure and cardiovascular death, with this effect mainly driven by a reduction in hospitalization for heart failure.